ABSTRACT: Embolization is a nonsurgical, minimally invasive procedure that deliberately blocks a blood vessel. Although several embolic particles have been commercialized, their much wider applications have been hampered owing mainly to particle size variation and uncontrollable degradation kinetics. Herein we introduce a microfluidic approach to fabricate highly monodisperse gelatin microparticles (GMPs) with a microshell structure. For this purpose, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of glutaraldehyde from the oil continuous phase to the suspending gelatin precursor droplets. A model micromechanic study, carried out in an artificial blood vessel, demonstrates that the extraordinary degradation kinetics of the GMPs, which stems from the microshell structure, enables controlled rupturing while exhibiting drug release under temporary chemoembolic conditions
■ INTRODUCTION
Embolization is the therapeutic procedure that deliberately blocks a blood vessel. 1 By occluding the blood vessel, thereby not allowing any supply of nutrients or oxygen, propagation of tumor cells can be suppressed to necrosis. Cancer therapy using well-engineered embolic agents has been of great interest owing mainly to their lesser side effects as well as enhanced curative effacements. 2−4 There are two embolic approaches. In mechanical embolization, a stent is placed to keep the aneurysm open and a coil is inserted in the bulging blood vessel. 5 This approach may have some potential risks in the aspect of dislodging and shape deformation, thus, usually displaying some limitations in completely blocking tremendous numbers of tiny blood vessels generated by tumors for their growth and survival. 6, 7 To overcome these difficulties, chemoembolization has recently emerged as a surgical technique that can improve the treatment effect and actual usability.
A number of embolic agents, including poly(vinyl alcohol) (PVA) particles, microfibrillar collagen particles, and gelatin particles, have been developed for chemoembolization. These chemoembolic agents have been developed with a variety of architectures, such as sponges, foams, and colloidal particles in micrometer scales, considering the types of organ, thickness of vessels, and tumor situations. 8 For example, PVA has been commercialized as a permanent embolic agent on the biomedical market owing to its easy availability and affordability as well as nonbiodegradability in the blood vessel. 9, 10 In principle, embolic agents should have size and shape uniformity. Irregular shape and sizes commonly cause incongruent sticking into blood vessels, eventually forming aggregates proximally. 11, 12 Furthermore, if the embolic agent is placed in the wrong blood vessel, it causes pain, fever, nausea, inflammation, and other complications. Therefore, there was no significant difference in the quantitative prescription to patients. For these reasons, there is a radical need to develop a new approach that allows the fabrication of chemoembolic agent with a controlled degree of vascular blocking as well as exactly scalable particle size and size monodispersity. 13 This study reports a straightforward approach for the synthesis of monodisperse gelatin microparticles (GMPs) that have the ability to block the target blood vessel site and exhibit controlled degradation therein. Gelatin is known as a temporary occlusive material. 14, 15 It is already widely used as a temporary embolic agent, mainly due to its biodegradability, which results in significantly reduced side effects, even in the cases where accidentally the wrong blood vessel is blocked. Furthermore, gelatin is one of the inducible proteins that exhibit excellent biocompatibility. When a gelatin solution is heated, the conformation of its chains converts from triple helices to randomly dispersed coils, thus showing a thermoreversible sol− gel transition. 16 To retain its gel structure, cross-linking should be inevitably conducted by incorporating cross-linkers, including glutaraldehyde (GA), genipin, 17 and alginate dialdehyde. 18 In this study, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of GA from the oil continuous phase to the suspending gelatin droplets, thereby inducing the formation of a microshell structure (Figure 1) . 19−21 Finally, we demonstrate the utility of the obtained microshell structures by employing them in the development of a new type of chemoembolic agents.
■ EXPERIMENTAL SECTION
Materials. Gelatin type A (from porcine skin, 300 g Bloom, H 2 O soluble 50 mg/mL, Sigma-Aldrich, U.S.A.) was used for preparation of microparticles. Glutaraldehyde (GA, 25 wt % water solution, SigmaAldrich, Germany) was used as a cross-linking agent. Olive oil (SigmaAldrich, Japan) and cetyl PEG/PPG-10/1 dimethicone (Abil EM 90, Evonik, Germany) were used as a continuous medium. Fluospheres carboxylate-modified microspheres (100 nm, red fluorescent, 2 wt % solid contents, Invitrogen, U.S.A.) were immobilized in the microparticles as a proxy of drug. Fluorescein isothiocyanate (FITC, SigmaAldrich, U.S.A.) and dimethyl sulfoxide (DMSO, Daejung, Korea) were used for characterization of the microshell structure. Phosphate buffered saline (PBS, pH 7.4, Sigma-Aldrich, U.S.A.), trypsin (from porcine pancreas, 13000−20000 BAEE unit/mg protein, SigmaAldrich, U.S.A.), pepsin (from porcine gastric mucosa, 3200−4500 units/mg protein, Sigma-Aldrich, U.S.A.) were formulated for mimicking an artificial blood fluid. All experiments used distilled (DI) water.
Fabrication of Capillary-Based Microfluidic Devices. Microcapillary-based microfluidic devices were fabricated by assembling tapered round capillaries. Tapering capillaries was conducted by heating and pulling cylindrical glass capillaries (outer diameter = 1.0 mm, inner diameter = 0.58 mm, World Precision Instruments, U.S.A.) using a pipet puller (Model P-97, Sutter Instruments, U.S.A.). The surface of capillary was hydrophobized by treating with a mixture of hexyltrimethoxysilane (1.0 wt %) and toluene for 2 min at room temperature. After the treatment, the capillary tubes were completely dried at 50°C for a fourth of the day. In succession, the tapered round capillary tube was inserted into a square capillary tube (inner diameter 1.0 mm, Atlantic International Technology, U.S.A.). Lastly, cut-down syringe needles (Korea Vaccine Co., Ltd., Korea) were completely glued at the junction between capillaries or their ends on a glass microscope slide.
Synthesis of GMPs from Emulsion Precursors. The dispersion fluid made with a gelatin aqueous solution (10 wt %) was produced by heating the solution at 40°C. The gelatin solution in a glass syringe (SGE, Australia) was injected from an inlet luer-stub connected through a polyethylene tube with an inner diameter of 0.86 mm (PE-5, Scientific Commodities, U.S.A.). We used olive oil as a dispersion fluid. To retain the fluidity of the gelatin solution, the microfluidic operation was conducted at 40°C in a temperature-controlled chamber. The combined injection of outer and dispersion fluids through the microfluidic device produced monodisperse water-in-oil (W/O) emulsion drops. The flow rate was controlled accurately by syringe pumps (Pump 11 Elite, Harvard Apparatus, U.S.A.). The gelatin emulsion precursors were produced stably at specific flow rates. The range of dispersion fluid flow rate was 20 to 1600 μL/h and the range of outer fluid flow rate was 500−3800 μL/h. Generation of emulsion drops in the microfluidic device was monitored with a highspeed camera (Phantom Miro EX2, U.S.A.). The gelatin emulsion precursor drops were then cross-linked in the presence of controlled amounts of GA for 1 day. After complete reaction, olive oil and other additives were washed out by repeated centrifugation at 1500 rpm for 5 min with water. The rinsed GMPs were then redispersed in water.
Measurement of Compressive Modulus of GMPs. For evaluation of the compressive modulus, GMPs dispersed in water were placed on a glass slide (76 × 26 × 1 mm, Marienfeld, Germany). The number of GMPs put on the glass glass was adjusted to exactly 32. The mean diameter of the GMPs was 112.4 μm. After compressing the GMPs with a pressure of 16 kPa, the change in the initial diameter of GMPs was monitored with a bright-field microscope (Axio Vert. A1, Carl Zeiss, Germany).
In Vitro Enzymatic Degradation. Degradation kinetics of GMPs was observed in a trypsin phosphate-buffered saline solution at 38°C. The concentration of trypsin was exactly tuned to 4 × 10 −4 wt %. We also conducted the same degradation experiment in a pepsin phosphate-buffered saline solution (pepsin = 4 × 10 −4 wt %) at 38°C . The time that was required for shape breakage or disappearance, we monitored the GMPs through a bright-field microscope equipped with imaging software (Jena GmbH, Carl Zeiss, Germany). In the case of observing any local decay or breakage of GMPs, Fluospheres were immobilized in the gel network of the GMPs. Then, we carried out time-lapse fluorescence image analysis for the GMPs. Cytotoxicity Test. Cytotoxicity was measured by Cell-Counting kit (CCK-8, Dojindo, Japan). NCTC clone 929 (L929) cells were dispersed to 100 μL of RPMI1640 (with L-glutamine and 25 mM of HEPES, 90% and heat inactivated fetal bovine serum (FBS), 10%) and NIH/3T3 cells were dispersed to 100 μL of DMEM (with 4 mM of Lglutamine, 4500 mg/mL of glucose, and a mixture of sodium pyruvate and heat inactivated fetal bovine serum (9/1, v/v)) in a 96-well plate for 5000 cells per well. Cells were incubated for 24 h in a humidified incubator at 37°C in the atmosphere of 5% CO 2 . A total of 10 μL of samples with given concentrations were added to the plate. Then, the plate was incubated for an appropriate period of time (24 and 48 h) in the incubator. A 10 μL aliquot of CCK-8 solution was added to each well of the plate. The plate was incubated for 1−4 h and its absorbance was measured at 450 nm using a microplate reader. To confirm reproducibility, additional experiments were carried out three times under the same conditions.
Capillary Micromechanics. A model capillary blood vessel was fabricated by tapering a round capillary using the pipet puller. The inner diameter of tapered capillary was controlled in the length scale of approximately 40 μm, compared to the dimension of a typical capillary blood vessel. Subsequently, this model capillary was filled with a trypsin solution containing a GMP with a diameter of ∼300 μm. The GMP used for this study was cross-linked with 0.01 wt % of GA. On filling in the model capillary with the trypsin solution, its inlet was connected to a balloon, inflated with air, which facilitates the GMP to clog the capillary channel under constant pressure. In this system, the pressure was set to 103.67 Pa. Under constantly pressurized conditions, the shape of the clogged GMP in the capillary tube was monitored using a fluorescence microscope.
■ RESULTS AND DISCUSSION
In a typical synthesis procedure, we first produced monodisperse water-in-oil (W/O) emulsion drops using the dropbased microfluidic technique (Figure 2 , see also Supporting Information). 22, 23 Olive oil with a nonionic surfactant, Abil EM 90 (1 wt %, cetyl PEG/PPG-10/1 dimethicone), was used as the outer fluid. Gelatin aqueous solution (10 wt %) was used as the dispersion fluid. 24 Coaxial jetting allowed the generation of monodisperse W/O emulsion drops, in which two immiscible solutions were passing through a capillary microchannel, and then the fluid thread was broken up into small emulsion droplets. When the balance of immiscible fluids becomes stable, the emulsion drops were generated with the constant frequency. It was critical to operate the microfluidic system above the gelatin gelling temperature, which is typically 40°C. Below this temperature, the drop size and jetting length of the fluid thread rapidly increased and after a while, the dispersion fluid stopped flowing. By tuning the flow rates of the three fluid streams, the gelatin emulsion drops were produced at rates from 10 2 to 10 3 Hz. Tight control over the particle size and shape uniformity is essential for GMPs-based high performance chemoembolization. Under optimized fluid formulations, the size of gelatin emulsion precursors could be controlled by simply tailoring the flow rate ratio of the dispersion fluid to the outer fluid. Monodisperse gelatin emulsion precursors with scalable sizes could be obtained by also changing the inner radius of exit internal capillaries ( Figure S1 ). Then, the gelatin emulsion precursors were cross-linked in the presence of a designated concentration of GA with shaking the suspension at 150 rpm for 24 h at 25°C. The concentration of GA was tuned from 2.5 × 10 −3 to 0.1 wt %. The condensation reaction between the amine group of gelatin chains and the aldehyde group of GA allowed the emulsion drops to solidify from the surface, given that GA molecules diffused from continuous phase. The modulus of GMPs was determined using a parallel plate Young's modulus test. 25 For this, the designated number of GMPs, which is 32, was sandwiched between two glass slides and was compressed by applying 16 kPa from the top cover (76 × 26 mm; Figure S2 ). We showed that the compressive modulus of GMPs was controllable in the range of 100−210 kPa, by varying the GA concentration. When the GA concentration was lowered to 2.5 × 10 −3 wt %, the GMPs were mechanically so fragile that they could not endure the applied stress. After complete cross-linking, the particle size of the GMPs could be controlled from tens of micrometers to hundreds of micrometers, while retaining the typical coefficient of variation in size less than 8.1% ( Figure 3A−C) .
Gelatin is degraded naturally in blood vessels. To evaluate the degradation kinetics of the GMPs synthesized in this study, in vitro degradation behavior was investigated in enzymatic conditions. Two different enzymes, trypsin, and pepsin, were used in our study: trypsin is a serine protease which cleaves the peptide bonds that link amino acid residues and pepsin is a C digestive enzyme that breaks down proteins into smaller peptides like trypsin. The degradation of GMPs was implemented using the method proposed by Roser and Kissel. 26, 27 First, the GMPs were added into PBS containing 4 × 10 −4 wt % pepsin at 37°C. Then, the degradation of GMPs was monitored daily using a time-lapse bright-field microscope ( Figure S3 ). GMPs showed tunable degradation, which was controlled by varying the cross-linking density in the degradation period of 2−27 days. To exactly characterize the degradation of GMPs, 100 nm sized Fluospheres, a proxy of drug, were physically immobilized in the gel network of GMPs. Moreover, to shorten the degradation period while displaying controlled drug release, degradation of Fluospheres-immobilized GMPs were monitored in the presence of 4 × 10 −4 wt % trypsin in PBS using a fluorescence microscope ( Figure 4A ). Under these enzymatic conditions, the GMPs rupture gradually into tiny fragments over a period of time. The rupturing time was exactly controllable by the GA concentration. We assumed that this extraordinary phenomenon was closely related to the network structure of GMPs.
To better understand the degradation of GMPs under enzymatic conditions, we tried to correlate their degradation kinetics with network structure. Basically, we determined the theoretical mesh size of the gelatin network by using the Peppas and Merrill equation (see Supporting Information). 28, 29 The mesh size of GMPs decreased from 33.8 to 5.9 Å, as the GA concentration increased (Figure 5A,B) . The swelling ratio of GMPs also showed the same pattern ( Figure S4 ). However, the rupturing time was gradually increased as the GA concentration increased. This implies that there must be a structure factor that deviates the correlation. To make the particle rupture favorable while maintaining the cross-linking density, the distribution of cross-link points should have a gradient from the surface to the core of the particle. The crosslinked gelatin network generated at the periphery of the particles would likely hinder the diffusion of GA. We could also observe that as we cross-link the GMPs, using the inbound diffusion of GA from the continuous phase, more favorable cross-linking occurred from the periphery of the particle, thus, resulting in the microshell particle morphology, as characterized in Figure 6A −C. In our continued work, we conducted an in vitro cytotoxicity test for GMPs before and after degradation. After coculturing GMPs with two types of mouse cells, NIH/ 3T3 cells and NCTC clone 929 cells, in the culture time from 12 to 48 h, we could confirm that there was no significant different in the cell proliferation between controls and GMPs (Figure 7) , thus, ensuring the applicability as embolic agents.
To show practical application to chemoembolization under enzymatic conditions, we placed a GMP in a model blood vessel made with a gradually tapered microcapillary. Under the conditions of applying a constant pressure (100 kPa) in the presence of trypsin (4 × 10 −4 wt %), the microcapillary was carefully clogged with a GMP cross-linked with 0.01 wt % of GA ( Figures 8A,B and S5) . Upon getting clogged, the surface of the GMP was tapered along the glass wall. As the enzymatic degradation progressed, the contact length of a particle at the glass wall (L) increased and the radius of the GMP (R) decreased. It was noticeable in our study that after a critical time of degradation, the GMP suddenly melted away (Figure 8C). To quantitatively characterize the change in the mechanical property during the degradation, we determined the compressive modulus, K, of the GMP from the degree of volume change associated with the applied compressive pressure. 30, 31 The pressure from the glass capillary wall, p wall , is obtained by balancing the external force from
, where α is the taper angle of the capillary and p is the applied hydrostatic pressure. Consequently, the compressive modulus can be expressed as = ε ε
, where ε r and ε z are the strains in the radial and longitudinal directions, respectively. We observed that L increased sharply after 105 min. For this reason, the GMPs lost their moduli after ∼105 min ( Figure  8D ). This sudden decrease in the K value at a critical degradation time was interpreted as having the microshell structure that enables precise control over the structural rupture in response to enzymatic degradation under pressure.
■ CONCLUSIONS
We have come up with a simple and intelligent method to fabricate monodisperse, biodegradable chemoembolic microparticles made with a natural gelatin. The monodispersity in the particle size of GMPs could be achieved using a drop-based microfluidic technique. We showed that the unique degradation behavior of the GMPs, which stemmed from their microshell structure, enabled controlled chemoembolization as well as drug release. A model micromechanic study, carried out in an artificial blood vessel, supported the utility of our GMPs for temporary chemoembolizations. These results highlight that our GMPs exhibit a great potential in the development of a new type of smart chemoembolic agent for cancer therapy with the abilities to be degraded at a target time while consecutively releasing the drug loaded in the gelatin gel network.
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